Abstract: Smoothened (SMO) belongs to the Hedgehog (HH) signaling pathway, which regulates cell growth, migration, invasion and stem cells in cancer. The HH signaling pathway includes both canonical and noncanonical pathways. The canonical HH pathway functions through major HH molecules such as HH ligands, PTCH, SMO and GLI, whereas the noncanonical HH pathway involves the activation of SMO or GLI through other pathways. The role of SMO has been discussed in different types of cancer, including breast, liver, pancreatic and colon cancers. SMO expression correlates with tumor size, invasiveness, metastasis and recurrence. In addition, SMO inhibitors can suppress cancer formation, reduce the proliferation of cancer cells, trigger apoptosis and suppress cancer stem cell activity. A better understanding of the role of SMO in cancer could contribute to the development of novel therapeutic approaches.

Keywords: Smoothened; Hedgehog signaling pathway; cancer stem cells

1. Introduction

The Hedgehog (HH) signaling pathway is a conserved pathway involved in cell growth and tissue patterning [1–5]. It regulates tissue homeostasis and stem cell behaviors, but the pathway becomes quiescent in adult tissues. Abnormal HH signaling can be found in cancer of the skin, brain, liver, prostate and breast; in malignant blood disease; etc. [6]. The canonical HH signaling pathway molecules include Hedgehog ligands (Sonic hedgehog, Indian hedgehog and Desert hedgehog), PTCH (PTCH-1 and PTCH-2), Smoothened and GLIs (GLI-1, GLI-2 and GLI-3). In the non-canonical SHH signaling pathway, SMO or GLIs are activated by other pathways such as the mammalian target of rapamycin–protein kinase B (mTOR-Akt), protein kinase A (PKA) or Rho [1–5]. SMO is an important target in cancer treatment. The efficacy of SMO inhibitors for treatment of malignancies of the breast, liver, pancreas and colon cancer has been demonstrated or is under clinical trials [7–9]. However, SMO mutations may lead to resistance against SMO antagonists. Here, current studies pertaining to the oncopathogenic roles of SMO and its inhibitors in cancer therapy are reviewed.

2. Canonical Hedgehog Signaling Pathway

The canonical HH signal pathway molecules include HH ligands, Patched receptors, the Smoothened receptor (SMO) and GLI transcription factors [7]. In addition, suppressor of fused protein (SUFU) is a negative regulator of HH signaling. SUFU mutations have been identified to
activate aberrant HH pathway in cancer HH ligands to bind to PTCH, and PTCH can thereby release the inhibition of SMO [10]. Three HH ligands (SHH, IHH and DHH) are involved in organ homeostasis and cell fate differentiation, and their expression are associated with cancer progression [11,12]. The activated SMO migrates to the cell plasma membrane and transduces signals to the nucleus via GLI proteins to turn on the expressions of target genes [1,2]. Its target genes are involved in cancer cell invasion, cell cycle, cell growth and stem cell activity. The aberrant activation of HH signaling pathway is associated with cancer development [13].

When the HH signaling pathway is in its off state, PTCH destabilizes SMO and SMO activity is inhibited by the binding of PTCH (Figure 1a). GLI proteins bind to SUFU repressors and are then processed by proteasome. GLI could be completely degraded or generated as a N-terminal truncated GLI repressor (GLI^R). GLI^R binds to HH target gene promoters and turns off their expression. In the on state, HH-producing cells release ligands in a spatially restricted manner, forming an HH protein gradient (Figure 1b) [14]. This process starts after an HH ligand binds to PTCH-1, and both of them are degraded in lysosomes. It could relieve the inhibition of SMO from PTCH, and then leads to the subsequent stimulation of G-protein-coupled receptor (GPCR)/SMO activity. GLI proteins are released from the inhibition of SUFU and are subsequently activated (GLI activated form, GLI^A), which triggers the expression of downstream target genes and activates their cellular functions [7]. Transcriptional targets of the HH signaling pathway include genes in different categories: (1) cell survival and cell proliferation (Bcl2, c-Myc, CDK and cyclin B1); (2) epithelial–mesenchymal transition (EMT), invasion, migration and metastases (Matrix metalloproteinases (MMPs) and SNAIL); (3) angiogenesis (Forkhead box F1 (FoxF1) and morphogenic protein 4 (BMP4)); and (4) chemotherapy resistance and cancer stem cell formation (PROM1 and CD133) [3].

**Figure 1.** Canonical Hedgehog (HH) signaling pathway. (a) OFF state: PTCH inhibits Smoothened (SMO) activity, and transcription factor GLI and SUFU are proteolytic by proteasome. The GLI repressor form (GLI^R) binds to target genes and there is no target gene expression. (b) ON state: HH ligands binds to PTCH to weaken the inhibition of SMO. SMO can then activate transcription factor GLI. The SUFU is removed from the binding to GLI. Therefore, GLI activator form (GLI^A) to regulate target gene expression related to Bcl2 gene for cell survival, c-Myc gene for cell proliferation, MMPs genes for migration/invasion, FoxF1 gene for angiogenesis and PROM1 for cancer stem cells.

### 3. Noncanonical Hh Signaling Pathway

Broadly speaking, noncanonical HH signaling describes any pathway that involves HH elements but differs from the usual signaling pattern [2]. Noncanonical HH signaling involves SMO or GLI activation via other pathways (GTPase, PKA, Rho or phosphoinositide 3-kinase (PI3K)/mTOR) (Figure 2). The noncanonical pathway acts as an alternative route when the canonical HH pathway fails to be activated. Therefore, noncanonical HH signal transduction could serve as an escape from the canonical HH signaling affected by cytotoxic or inflammatory stress [15].
SMO-dependent noncanonical pathway could control the metabolism [16]. SMO is a functional of G-protein-coupled receptors (GPCRs), including N-terminal cysteine rich domain (CRD), extracellular loops, seven transmembrane domain and an intracellular C-terminal domain [17]. SMOSmo-heterotrimeric G-inhibitory (Gi) family proteins coupling could regulate calcium (Ca\(^{2+}\)) flux, RhoA and Rac activation (Figure 2) [18,19]. SMO activates these molecular switches and targets specific molecules that modulate noncanonical HH signaling responses [4]. Active Gai can negatively regulate adenylyl cyclase, thereby inhibiting intracellular cAMP and PKA activity [5]. SMO-dependent, noncanonical HH signaling also elicits specific cellular responses via the activation of small G-proteins (GTPases). Small GTPases are monomeric G proteins that, acting as molecular switches, can regulate cellular function. Moreover, guanine-exchange factors (GEFs) activate small GTPase-bound guanosine-5′-triphosphate (GTP) when in the on state. GTPases are then inactivated by the hydrolysis of the bound GTP to guanosine diphosphate (GDP), an intrinsically slow process facilitated by GTPase-activating proteins (GAPs).

SMO can be activated by some protein kinases in non-canonical pathways such as Rho, Rac, Src and PI3K/phospholipase C gamma (PLC\(\gamma\)), as well as secondary messengers such as calcium (Figure 2). It can affect cytoskeletal arrangement and cellular migration [4]. Small GTPases may be categorized into four families: Ras, Rho, Arf and Rab. The Rho family, which mediates cytoskeletal reorganization, can be further divided into three subfamilies: Rho, Rac and Cdc42. These subfamilies regulate cytoskeletal rearrangements through the polymerization of actin filaments, and different rearrangements allow the coordination essential to cell motility [4]. Therefore, SMO-dependent noncanonical HH signaling could affect cellular migration and contribute to the cancer progression [2].

4. SMO and Breast Carcinoma

Breast carcinoma is the most common cancer among women worldwide [20]. Classified based on the expression of hormone (estrogen or progesterone) receptors (HR) and human epidermal growth factor receptor 2 (HER2), breast cancer includes four subtypes: (1) HR+/Her2− (luminal A);
(2) HR+/Her2+; (3) HR−/Her2+; and (4) triple-negative breast cancer (TNBC), which is negative for estrogen receptor (ER), progesterone receptor (PR) and Her2 [21]. TNBC is more aggressive than the other types and is associated with poor prognosis because it usually fails to respond to standard adjuvant therapy and exhibits cancer-stem-cell-like characteristics [22,23].

The HH/SMO signaling pathway plays an important role in breast cancer development, progression, invasion and metastasis [24–26]. The pathway regulates breast tumorigenesis affecting cell proliferation, self-renewal, maintenance of cancer stem cells and epithelial–mesenchymal transition (EMT) [27–29]. The activation of SMO plays an essential role in the development of dysplasia of the mammary ducts [29–31]. SMO exists in both ductal carcinoma in situ (DCIS) and invasive breast cancer (IBC) but is not present in normal tissues [30]. Overexpression of SMO is associated with tumor size, lymph node metastasis and postoperative recurrence [32]. Therefore, HH signaling pathway molecules could be indicators for recurrent breast carcinoma.

In ER+ subtype breast cancer, estrogen triggers the overexpression of SHH and GLI1. It activates SHH signaling and enhances cancer cell invasiveness of the ER-positive T47D (HER2−) and BT-474 (HER2+) cells [33]. There may be cross-talk between ER- and SHH-signaling pathways facilitating the invasiveness of ER-positive cancer cells [29]. Triple-negative breast cancer (TNBC) presents a moderate amount of basal-like progenitors that retain the primary cilia characteristics [34,35]. The SHH signaling pathway orchestrates the angiogenesis in TNBC [34]. Overexpression of Hedgehog molecules SMO and GLI1 exists in breast cancer and mammary hyperplasia, which can affect histological grade or tumor stage in TNBC [36]. In addition, the upregulation of HH pathway molecules were found in positive lymph nodes-positive breast cancer cases. The HH signaling pathway probably affects the activation of cancer stem cells and the progression, invasion and metastasis of TNBC. In in vivo studies, SHH overexpression facilitated the growth of orthotopic xenograft and the lung metastasis [37]. Canonical SHH signaling triggers angiogenesis of TNBC via metalloproteases (MMPs), cysteine-rich angiogenic inducer 61 (Cyr61, CCN1) and vascular endothelial growth receptor 2 (VEGFR2), enhancing growth and metastasis [29,34,37,38]. SHH pathway affects bone metastasis, with osteolysis in TNBC [29]. In TNBC cell line MDAMB231, the HH signaling pathway promotes the migration and invasion of breast cancer cells via carbonic anhydrase (CA) XII [39]. In in vitro studies, overexpression of SHH enhanced cell proliferation, colony formation, migration, and invasion of TNBC [37,40]. However, another study demonstrated that SMO expression did not correlate with patient age or metastasis, but correlated with earlier onset of TNBC [26].

The cancer microenvironment/stroma consists of endothelial cells, immune cells, adipocytes and cancer-associated fibroblasts (CAFs) [41]. CAFs fuel cancer cells via the secretion of soluble factors that trigger metastasis and chemoresistance [42–45]. The microenvironment of breast cancer is affected by the type II noncanonical SHH signaling pathway, which can enhance cancer development and metastasis [5,29,46]. This process includes extracellular acidification, inflammation and activation of matrix metalloproteases [42,47,48]. In such a microenvironment, the tumor-associated macrophages with aberrant genetic and epigenetic changes trigger overexpression of signaling molecules that prolong the tumor cells’ survival [49].

Inhibitors targeting the signaling pathway of SHH, Notch, cyclin-dependent kinases (CDKs), mTOR and WNT have become promising treatment strategies [49]. HH inhibitors may emerge as valuable therapeutic option in the future [34]. Ruiz-Borrego et al. used a combination of sonidegib (LDE225) (a small molecular, oral inhibitor of the SMO/SHH pathway) and docetaxel (a drug for metastatic breast cancer) to treat advanced TNBC in a phase Ib clinical trial study [50]. The results show one patient with a complete response and two patients with long-lasting stabilizations out of ten patients. According to Benvenuto’s study, a SMO inhibitor (GDC-0449) and GLI inhibitor (GANT-61) targeting the SHH/GLI pathway suppressed cell growth both in vitro and in vivo [51]. Therefore, downstream SMO targeting seems to be superior to upstream SMO targeting in interrupting the HH signaling in breast cancer [51]. Cyclopamine could directly bind to SMO and regulates the expression of Hedgehog molecules SHH, PTCH1, GLI1 and GLI2. It could decrease growth of human breast
cancer cells [52]. Breast cancer cells-condition medium with cyclopamine could interfere osteoclast activity [53]. SMO inhibitor cyclopamine decreased SMO, GLI and CD44 expression and reduced cell proliferation of breast cancer stem cells for chemoresistance [27,54–56]. Cyclopamine significantly reduced the invasiveness and estrogenic potency in breast cancer [57]. Therefore, targeting SMO could be an effective way to treat breast cancer.

5. SMO and Liver Cancer

Hepatocellular carcinoma remains one of the leading causes of cancer-related death in Asian countries [58]. HCC is the most common primary liver cancer, comprising 80% of cases [59]. The causes of liver fibrosis to HCC can include the responses to viral hepatitis, alcohol, steatosis, autoimmune diseases, etc. [60–63]. These factors can induce a harmful inflammatory reaction and repeated chronic liver injury, eventually resulting in hepatocarcinogenesis [60,64]. Surgical resection and liver transplantation (LT) remain the mainstay treatment for HCC [65,66]. However, HCC has a 50–75% five-year recurrence rate after the surgery [67].

The Hedgehog signaling pathway is highly activated in HCC patients [68,69]. It plays a role in hepatocarcinogenesis, invasiveness, recurrence and HCC cancer stem cells [70,71]. Transformation of HBx (HBV gene product HBx protein) can activate the HH signaling pathway. SMO is an important regulator in the repair of adult liver tissue and plays a key role in the promotion of epithelial–mesenchymal transition (EMT) during early hepatocarcinogenesis [72]. SMO expression in primary hepatocytes may be upregulated after Fas-induced liver injury and holds potential value as a prognostic factor in HCC patients [73]. Overexpression of SMO induces the expression of c-Myc, which plays a significant role in hepatocarcinogenesis and SMO overexpression is correlated with tumor sizes [74]. Overexpression of HH signaling molecules predicts a higher risk of postoperative HCC recurrence [68]. The activation of HH signaling enhances the G2–M transition following overexpression of cyclin B1 and cyclin-dependent kinase 1 (CDK1), facilitating cell proliferation [75]. Moreover, the overexpression of SMO mRNA is present in cancer stem cell CD133+ mouse liver cell line Hepa1-6 [76]. In addition, SMO polymorphisms in transplant recipients may increase the risk of HCC recurrence following liver transplantation [77]. This evidence could be clinically valuable when determining the prognoses of HCC cases. The C-terminal lysine mutation (K575M) in SMO can affect the binding between SMO and PTCH, and is able to release SMO from PTCH inhibition [70].

The SMO inhibitor cyclopamine has been shown to reduce DNA synthesis, resulting in inhibition of the cell growth, invasiveness, and motility of HCC cells [78]. In addition, cyclopamine suppresses cell viability and increases apoptosis after downregulating Bel-2 in HCC cells [73]. Sicklick et al. also found that 3-keto-N-aminoethylcaproyldihydrocinnamoyl cyclopamine (KAAD-cyclopamine) can inhibit HH signaling activity and expression of Myc, as well as reducing the growth rate of Hep3B cells [74]. Kim et al. reported that HCC cells harboring SMO mutations are otherwise unresponsive to KAAD-cyclopamine [79]. The administration of SMO antagonist GDC-0499 resulted in the inhibition of hepatocarcinogenesis in HBx transgenic mice [80]. Jeng et al. reported that cyclopamine or GDC-0499 decreased expression of HH genes and reduced HCC cell growth in a mouse model [81,82]. Moreover, GDC-0449 reduced the cell migration, invasion and metastasis to lung of chondroitin sulfate synthase 1 (CHSY1)-induced HCC cells [83]. In a Phase I study, the pharmacokinetics and safety of GDC-0449 was evaluated in patients with HCC or hepatic impairment. However, the results are difficult to tell the adverse events from advanced HCC or GDC-0449 exposure [84]. Further study is required to verify clearly how to regulate HH signaling mitigate HCC progression with minor adverse events [85]. Overall, there is a consensus that SMO inhibitors may represent a potentially beneficial strategy against hepatocarcinogenesis [86].

6. SMO and Pancreatic Cancer

Pancreatic cancer is one of the most highly invasive of the solid cancers and actively communicates with the desmoplastic stroma [87]. The aberrant expression of SHH is correlated with oncogenic Kras,
which is highly mutated in pancreatic ductal adenocarcinoma (PDAC) [88]. It has been shown that Shh is a target gene of NF-κB, which is constitutively active in pancreatic cancer [89]. Accordingly, both canonical and noncanonical HH signaling are present in the tumor cells, but ligand-dependent HH signaling mainly exists only in stromal cells [90]. SMO plays an important role in the development of pancreatic cancer cell metastasis [91]. It has also been shown that SMO is upregulated in cancer-associated fibroblasts (CAF), the predominant stromal cell type, comparing with normal pancreatic fibroblasts [92]. Hypoxia found in pancreatic ductal adenocarcinoma increased the transcription of SHH, SMO and GLI-1 and activated the SHH pathway to promote invasiveness [93]. Meanwhile, tumor necrosis factor-alpha and interleukin-1 beta in the hyperplasia stroma enhanced the carcinogenesis of pancreatic ductal adenocarcinoma via activation of the HH pathway [94]. The knockdown of SMO could inhibit pancreas cancer cells in terms of self-renewal, epithelial–mesenchymal transition (EMT), invasion, migration, lung metastasis, chemoresistance to gemcitabine and development of pancreatic cancer stem cells [95]. SMO regulated EMT, invasion and migration of pancreatic cancer stem cells [95]. Thus, the dysregulated SMO in pancreatic cancers could be a therapeutic target [96].

A novel GDC-0449 analog was used to decrease side effects in pancreatic cancer treatment [91]. AZD8542, a novel HH antagonist, inhibited the progression of pancreatic cancer with an emphasis on the role of the stroma compartment [97]. The ablation of the SMO gene in stromal fibroblasts caused increased proliferation of pancreatic tumor cells and the activation of oncogenic protein kinase B (AK1) in fibroblasts [98]. A SMO inhibitor increased the intratumoral vasculature [99]. In a mouse model, this inhibition facilitated the delivery of chemotherapy drugs in treating pancreatic cancer [99]. GDC-0449 has been shown to downregulate HH signaling and to decrease fibroblast-induced doxorubicin resistance [100]. Moreover, the genetic ablation of SMO in stromal fibroblasts in a Kras G12D mouse model disrupted paracrine HH signaling and increase acinar-ductal metaplasia [101]. Fibroblasts with SMO deletion exhibited overexpression of transforming growth factor-alpha (TGF-α), leading to the activation of epidermal growth factor receptor signaling in acinar cells [101].

7. SMO and Colon Cancer

Colon cancer is one of the most common gastrointestinal cancers worldwide [102]. Colorectal cancer is the second most common cause of cancer death in the United States. SMO affects colon cancer progression and can act as a biomarker for liver metastasis [103]. Increased SMO expression was found in colon cancer tissues compared to normal tissues via immunohistochemistry staining. The level of SMO expression is correlated with metastasis and T stage. In addition, SMO expression in colorectal cancer correlates with patients’ outcome [104]. Colon cancer presents a heterogeneous tumor type with a subpopulation of cancer stem cells. WNT and HH signaling components are increased in cancer stem cells according to whole-transcriptome analysis [105]. In colon tissue, the ratio of SMO and GLI protein expression is increased significantly in cancer and adenoma tissue compared with normal colon tissue [106]. However, some studies still question the exact role of the HH signaling in the carcinogenesis and progression of colon cancer [107–109]. The mutations of the SMO protein (A324T, V404M and T640A) in colon cancer produced no aberrant HH signaling activity [107]. Chatel et al. showed that the expression of the HH pathway members was impaired in colon cancer cell lines [108]. Although SHH was upregulated, Gerling et al. demonstrated that the downstream activity of HH signaling decreased in colon cancer [109]. Activation of stromal HH was able to suppress a colonic tumor via modulating BMP signaling and restricting colonic stem cells [109].

Despite these controversies, most investigators agree that SMO is a potential target for colon cancer treatment [39]. SMO inhibitor GDC-0449 suppresses colon cancer cells proliferation and triggers apoptosis via the downregulation of Bcl-2 [110]. GDC-0499 is used to inhibit and modulate cellular plasticity and invasiveness in colorectal cancer [111]. Therefore, SMO could be a potential treatment target for colon cancer [96].
8. Pharmacological Studies of SMO Inhibitors in Other Cancers

Based on the results described above, SMO-related inhibitors have shown anti-cancer ability in vitro and in vivo, even in clinical trials (Table 1). Many SMO inhibitors could bind to the seven-transmembrane of SMO and were under investigation for clinical application [112]. Vismodegib (GDC-0499, ERIVEDGE™), erismodegib (LDE-225, sonidegib) and glasdegib have been approved by the Food and Drug Administration (FDA) for treatment of basal cell carcinoma. Vismodegib has been used as a monotherapy or in combination with some chemotherapeutics in the clinical trials for the treatment of medulloblastoma, meningeoma, glioblastoma, small-cell cancer, metastatic prostate cancer, metastatic pancreatic cancer, etc. [113]. However, vismodegib in combination with gemcitabine was not superior to gemcitabine alone in clinical trials with metastatic pancreatic adenocarcinoma patients [114]. Another clinical trial suggested that a benefit of vismodegib in combination with either Folinic acid, Fluorouracil, Oxaliplatin (FOLFOX) or Folinic acid, 5-FU, IRInotecan (FOLFIRI) was not found in colorectal cancer [115].

Table 1. Hedgehog/Smo drugs in different cancer types

| Cancer Type         | Treatment                        | Level of Evidence          | References    |
|---------------------|----------------------------------|----------------------------|---------------|
| Breast cancer       | LDE-225 combined with docetaxel   | Phase 1b                   | [50]          |
|                     | GDC-0449                          | in vitro and in vivo        | [51]          |
|                     | Cyclopamine                       | In vitro                   | [27, 54–57]   |
| Liver cancer        | Cyclopamine                       | in vitro and in vivo        | [73, 79, 83]  |
|                     | KAAD-cyclopamine                  | in vitro                   | [74]          |
|                     | GDC-0499                          | in vitro and in vivo        | [80, 81, 83]  |
| Pancreatic cancer   | MDB5                              | in vitro and in vivo        | [91]          |
|                     | AZD8542                           | in vivo                    | [97]          |
|                     | IPI-926 (saridegib)               | in vivo                    | [100]         |
|                     | GDC-0449                          | in vivo                    | [99]          |
|                     | BMS-833923                        | in vivo                    | [116]         |
|                     | TAK-441                           | in vivo                    | [117]         |
| Colon cancer        | GDC-0449                          | in vitro                   | [110, 111]    |
| Basal cell carcinoma| GDC-0499                          | FDA approved               |               |
|                     | LDE-225                           | FDA approved               |               |
|                     | PF-04449913 (glasdegib)           | FDA approved               |               |
|                     | CUR6414                           | in vivo                    | [118]         |
| Medulloblastoma     | BMS-833923                        | in vivo                    | [116]         |
|                     | TAK-441                           | in vivo                    | [119]         |
| Acute myelogenous leukemia | PF-04449913 (glasdegib) | Phase 1                   | [120]         |

Mechanism: SMO inhibitors LDE225, GDC-0449, cyclopamine, KAAD-cyclopamine, IPI-926, BMS-833923 and PF-04449913 (glasdegib) could bind to 7TM domain of SMO.

Erismodegib (LDE-225, sonidegib), another SMO antagonist, influences cancer stem cell activity and decreases the invasiveness of glioblastoma, renal-cell cancer and prostate cancer [121–123]. Saridegib (IPI-926), a modified form of cyclopamine, increased the delivery of gemcitabine to pancreatic ductal cancer in a mouse model [99]. It can potentially inhibit lung tumor and cholangiosarcoma xenografts [124, 125]. CUR6414 directly binds to SMO to treat basal cell carcinoma [105], while BMS-833923 directly binds to SMO, reducing the growth of medulloblastoma, pancreatic cancer and cholangiocarcinoma in xenograft mice [116, 126]. PF-5274857, a selectively potent SMO antagonist, can penetrate the blood-brain barrier to treat brain tumors or metastasis [127]. TAK-441, an oral SMO inhibitor, suppressed medulloblastoma and pancreatic cancers in mice, as well as mitigated the progression of prostate cancer in mouse xenograft models [119, 128].

For acute myelogenous leukemia (AMC), the combined use of a SMO inhibitor LDE225 (sonidegib) or PF-04449913 (glasdegib) with the conventional drugs were demonstrated [117]. Two possible
mechanisms have been proposed: direct affecting the intracellular pathway and indirect overcoming the drug resistance. Such combined therapy paves an innovative strategy for treatment of AML [111]. In a Phase I study of PF-04449913, 100 mg was a safe dose in Japanese patients with advanced hematologic malignancies [120]. SMO-related inhibitors could have anti-cancer ability in vitro or in vivo, even in clinical trials (Table 1). Three drugs, GDC-0449, LDE225 and PF-04449913 (Glasdegib), are FDA-approval drugs for basal cell carcinoma.

However, the resistance to SMO inhibitors remains a challenge. The resistance could be from SMO mutation, SUFU deletion, GLI-2 amplification or other mechanisms [129]. Mutations of D473G or W533L of the SMO receptor could lead to the resistance to vismodegib by reducing the binding affinity [130]. Many smo-related drugs (GDC-0449, erismodegib, saridegib, ZSP1-1602, NVP-LEQ-506, glasdegib and taladegib) are still under trials, and the studies of possible side effects are ongoing (Table 2). GDC-0449 has had several Phase 1, 2 and 4 clinical trials with different indications, such as solid tumors, pancreatic cancer, medulloblastoma and metastatic BCC. The next generation of novel SMO inhibitors must overcome the obstacle/resistance of SMO mutations [113,131].
Table 2. SMO drug in clinical trials (last updated in 2020, Jan-July)

| Drug                  | Indication                                                                 | FDA Approval Status     | Trial Status            | NCT#     |
|-----------------------|-----------------------------------------------------------------------------|------------------------|------------------------|----------|
| GDC-0449              | plasma-cell myeloma, metastatic solid tumor, B-cell non-Hodgkin lymphoma    | Phase 2                | Recruiting             | NCT03297606 |
|                       | tumor, neoplasia, cancer                                                  | Phase 2                | Not yet recruiting     | NCT04341181 |
|                       | lymphoma, advanced solid tumor, advanced multiple myeloma                  | Phase 2                | Recruiting             | NCT02465960 |
|                       | cancer                                                                      | Phase 2                | Recruiting             | NCT03498521 |
|                       | advanced chondrosarcoma                                                   | Phase 2                | Active, not recruiting | NCT01267955 |
|                       | metastatic pancreatic cancer or solid tumors                               | Phase 1                | Active, not recruiting | NCT00878163 |
|                       | grade 4 astrocytoma                                                        | Phase 1/Phase 2        | Recruiting             | NCT03158389 |
|                       | primary neuroectodermal tumor, medulloblastoma                             | Phase 2                | Recruiting             | NCT01878617 |
|                       | solid tumor, glioblastoma, plasma cell myeloma, ovarian cancer, metastatic solid tumor, B-cell non-Hodgkin lymphoma | Phase 2                | Recruiting             | NCT02925234 |
|                       | metastatic basal-cell carcinoma                                           | Phase 3                | Recruiting             | NCT03416179 |
|                       | chronic/myelomonocytic leukemia                                            | Phase 2                | Active, not recruiting | NCT02367456 |
|                       | chronic myelomonocytic leukemia, myelodysplastic syndrome                  | Phase 2                | Active, not recruiting | NCT01842846 |
|                       | myelodysplastic syndrome                                                   | Phase 2                | Active, not recruiting | NCT02367456 |
|                       | glioblastoma                                                               | Phase 1/2               | Recruiting             | NCT03466450 |
|                       | relapsed acute myeloid leukemia                                            | Phase 1/2               | Recruiting             | NCT03390296 |
|                       | acute myeloid leukemia                                                     | Phase 2                | Completed              | NCT01546038 |
|                       | acute myeloid leukemia                                                     | Phase 2                | Recruiting             | NCT04051996 |
|                       | acute myeloid leukemia                                                     | Phase 2                | Recruiting             | NCT04231851 |
|                       | acute myeloid leukemia with myelodysplasia-related changes                 | Phase 2                | Recruiting             | NCT04231851 |
|                       | solid tumor, pancreatic adenocarcinoma, non-small cell lung cancer, colorectal cancer, metastatic urothelial carcinoma, metastatic solid tumor, metastatic pancreatic adenocarcinoma, metastatic melanoma, metastatic gastric adenocarcinoma, metastatic colorectal cancer, malignant urothelial neoplasm, head and neck squamous cell carcinoma, medulloblastoma, basal cell carcinoma | Phase 1                | Recruiting             | NCT04007744 |
|                       | LDE225/erismodegib                                                        | Phase 1                | Recruiting             | NCT03434262 |
|                       | basal-cell nevus syndrome                                                  | Phase 2                | Not yet recruiting     | NCT00880308 |
|                       | basal-cell carcinoma                                                      | Phase 2                | Not yet recruiting     | NCT04303895 |
|                       | Taladegib                                                                  | Phase 1/Phase 2        | Active, not recruiting | NCT02530437 |
|                       | gastroesophageal junction adenocarcinoma                                    | Phase 1                | Completed              | NCT02784795 |
|                       | malignant solid tumor, metastatic lymphoma, advanced colon cancer, advanced breast cancer, cholangiocarcinoma, metastatic refractory colon cancer, metastatic soft tissue sarcoma | Phase 1                | Completed              | NCT01106508 |
|                       | NVP-LEQ-506                                                               | Phase 1                | Completed              | NCT03734913 |
|                       | advanced solid tumor                                                      | Phase 1                | Recruiting             | NCT03734913 |
9. Using SMO Antagonists to Inhibit Cancer Stem Cells

Cancer stem cells (CSC) are a subpopulation of cancer cells that retain the characteristics of self-renewal and self-sustenance [131]. They are usually involved in development, progression, recurrence and metastasis of tumors. They also contribute to drug resistance in chemotherapy [131,132]. SHH/SMO/GLI affects EMT to induce the polarized epithelial cells transformation with active motility. Such cells trigger the invasiveness and metastasis of cancer [105,132].

SHH/SMO signaling pathway activates in cancer stem cells (CD133+) of the mouse hepatoma cell line Hepa1-6 [86]. CD133+ HCC cells with upregulated SMO mRNA have significantly higher colony proliferation and clonogenicity than CD133- HCC cells [76]. BMS-833923, a SMO inhibitor, significantly inhibits osteoblast differentiation of human mesenchymal stem cells (hMSCs) causing in a decrease of alkaline phosphate activity and a decrease of osteoblast-related gene expression and in vitro mineralization [133]. CD44 with overexpression of HH/SMO pathway genes and some self-renewal marker proteins (SOX2, OCT4 and NANOG) in several gastric cancer cell lines were found [134]. SMO shRNA or inhibitors can significantly suppress the spheroid formation and tumor growth of gastric cancer cell lines. Furthermore, HH/SMO inhibition could be helpful to reverse the chemoresistance of CD44+ spheroid gastric cancer cells to 5-fluorouracil and cisplatin [134].

There are some proposals of mechanisms of cancer stem cell formation. Genetic mutations induced by endogenous or exogenous stimuli transform adult stem cells into cancer stem cells [135–138]. The main signaling pathways involved include Hedgehog, Wnt, Notch, BMP, PI3K/Akt, etc. [139]. Many lines of evidence support the idea that SHH signaling is important in maintaining cancer stem cell in various cancers [12,140–142]. Neoplasms with activated SHH signaling pathway in cancer stem cells consist of glioblastoma, chronic myeloid leukemia, multiple myeloma, hepatocellular carcinoma and cancers of the colon, breast and pancreas [7].

Drug resistance develops following SHH/SMO/GLI signaling, upregulating drug-transport-pump expression in cancer stem cells [131]. SHH/SMO inhibitors have been shown to inhibit the CSCs of some cancers, including pancreatic cancer (ALDH+ cells), colon cancer (CD133+ cells), breast cancer (CD44+CD24− cells) and gastric cancer (CD44+ cells) [143–146]. Combining SHH/SMO/GLI inhibitors and chemotherapy, radiation therapy, or immunotherapy to target CSCs has become a promising treatment [132]. A SMO inhibitor, 2-chloro-N1-[4-chloro-3-(2-pyridinyl)phenyl]-N4,N4-bis(2-pyridinylmethyl)-1,4-benzenedicarboxamide (MDBS) (an analog of GDC-0449), seemed to be more effective than GDC-0449 in treatment of pancreatic CSC M1A PaCa-2 cells [91]. MDBS downregulated ALDH1, CD44, Oct-3/4 (key tumor markers of pancreatic CSC), Bcl-2, GLI-1 and SHH and upregulated Bax. In ER-positive breast cancer cells remodeling of the cancer microenvironment could facilitate an antioxidant response to SHH signaling to enhance the CSC activity [147].

SMO inhibitor vismodegib (GDC-0449) significantly suppressed cell proliferation, cell invasion and mammosphere formation of a TNBC stem-cell line [135]. It also inhibited the protein expression and phosphorylation of downstream signaling molecules to induce cell apoptosis. In a xenograft mouse model, pretreatment of HCC1806 cells (a TNBC stem cell line), with vismodegib significantly inhibited tumor growth [135]. This evidence shows that SMO antagonists can target breast CSCs. This has a potential as a promising strategy in clinical applications for TNBC [148].

10. Conclusions

In cancer, the Hedgehog molecule SMO interacts directly or indirectly with several molecules, including MMPs, BMP4, Rho, CCN1, etc. (Figure 3). SMO antagonists such as vismodegib, cyclopamine, erismodegib, saridegib, BMS-833923 and TAK-441 have been identified (Figure 3). SMO antagonists have been approved for clinical use or clinical trials in treating a variety of cancers (Table 2) [149]. SMO seems to be an important drug target, with a deep, pocket-like structure that allows efficient and selective drug binding. In addition, SMO inhibitors serve as another strategy against cancer stem cells [150]. Thus, SMO represents a promising therapeutic target for the inhibition of HH signaling in the treatment of a spectrum of malignancies [151]. The current clinical impact of SMO antagonists
has been emphasized recently in cancer therapy, especially for a variety of solid tumors [7]. Such treatments could be beneficial to patients, either with a single use or as an adjuvant or adjunct to conventional chemotherapy [132].

The intra-tumor heterogeneity needs to be taken into consideration when considering cancer therapies, because this heterogeneity can contribute to tumor progression [152]. Heterogeneity also increases the difficulty of cancer treatment. More importantly, some mutations can lead to the resistance to SMO antagonists. SMO mutations that impair drug binding to SMO can occur at multiple levels [153]. It is necessary to discover new SMO antagonists [154]. Combined use of drugs to target different components at different levels of the HH pathway may be able to improve the issue of drug resistance [154]. Further study of the structural analogs and detailed mechanisms of hedgehog inhibitors, including the noncanonical pathway, is needed. The strategy for Hedgehog inhibitor alone or combination with other anticancer drug needs to overcome known drug resistance and adverse events [155]. A better understanding of the HH/SMO pathway could be useful for developing a new class of clinically efficient drugs.

**Author Contributions:** K.-S.J., I.-S.S., C.-M.L., P.-H.T. and C.-F.C. searched related references and prepared the draft, figures and revised version of manuscript. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by The Far Eastern Memorial Hospital-National Yang–Ming University Joint Research Program, grant numbers 107DN17, 108DN28, 109DN03 and 109DN28; Far Eastern Memorial Hospital, grant number FEMH-2020-C-002; and the Ministry of Science and Technology, Taiwan, grant numbers MOST 106-2314-B-418-001-MY3, MOST 109-2314-B-418-007 and MOST 109-2314-B-418-014.

**Acknowledgments:** We appreciate the support from the Core Laboratory of Far Eastern Memorial Hospital, Taiwan.

**Conflicts of Interest:** All authors declare no conflict of interest.
Abbreviations

SMO Smoothened
HH Hedgehog
mTOR-Akt Mammalian target of rapamycin-protein kinase B
PKA Protein kinase A
SUFU Suppressor on fused homolog
GPCR G-protein-coupled receptor
EMT Epithelial-mesenchymal transition
MMPs Matrix metalloproteinases
FoxF1 Forkhead box F1
BMP4 Morphogenetic protein 4
PI3K Phosphoinositide 3-kinase
CRD Cysteine rich domain
Gi G inhibitory
GEFs Guanine exchange factors
GTP Guanosine-5′-triphosphate
GDP Guanosine diphosphate
GAPs GTPase-activating proteins
PLCγ Phospholipase C gamma
HR Hormone receptor
HER2 Human epidermal growth factor receptor 2
TNBC Triple negative breast cancer
ER Estrogen receptor
PR Progesterone receptor
DCIS Ductal carcinoma in situ
IBC Invasive breast cancer
Cyr61 Cysteine-rich angiogenic inducer 61
VEGFR2 Vascular endothelial growth receptor 2
CA Carbonic anhydrase
CAF Cancer-associated fibroblasts
CDKs Cyclin-dependent kinases
LT Liver transplantation
HBx HBV gene product HBx protein
CDK1 Cyclin-dependent kinase 1
CHSY1 Chondroitin sulfate synthase 1
FDAC Pancreatic ductal adenocarcinoma
TGF-α Transforming growth factor-alpha
FDA Food and Drug Administration
FOLFOX Folinic acid, Fluorouracil, Oxaliplatin
FOLFIRI Folinic acid, 5-FU, IRInotecan
AMC Acute myelogenous leukemia
CSC Cancer stem cell
hMSCs Human mesenchymal stem cells

References

1. Kong, J.H.; Siebold, C.; Rohatgi, R. Biochemical mechanisms of vertebrate hedgehog signaling. Development 2019, 146, dev166892. [CrossRef] [PubMed]
2. Marini, K.D.; Payne, B.J.; Watkins, D.N.; Martelotto, L.G. Mechanisms of Hedgehog signalling in cancer. Growth Factors 2011, 29, 221–234. [CrossRef] [PubMed]
3. Chapouly, C.; Guimbal, S.; Hollier, P.-L.; Renault, M.-A. Role of Hedgehog Signaling in Vasculature Development, Differentiation, and Maintenance. Int. J. Mol. Sci. 2019, 20, 3076. [CrossRef] [PubMed]
4. Brennan, D.; Chen, X.; Cheng, L.; Mahoney, M.; Riobo, N.A. Chapter three—Noncanonical Hedgehog Signaling. In Vitamins & Hormones; Litwack, G., Ed.; Academic Press: Cambridge, MA, USA, 2012; Volume 88, pp. 55–72.

5. Pandit, T.; Ogden, S.K. Contributions of Noncanonical Smoothened Signaling During Embryonic Development. J. Dev. Biol. 2017, 5, 11. [CrossRef]

6. Montagnani, V.; Stecca, B. Role of Protein Kinases in Hedgehog Pathway Control and Implications for Cancer Therapy. Cancers 2019, 11, 449. [CrossRef]

7. Espinosa-Bustos, C.; Mella, J.; Soto-Delgado, J.; Salas, C. State of the art of Smo antagonists for cancer therapy: Advances in the target receptor and new ligand structures. Future Med. Chem. 2019, 11, 617–638. [CrossRef]

8. Carpenter, R.L.; Ray, H. Safety and Tolerability of Sonic Hedgehog Pathway Inhibitors in Cancer. Drug Saf. 2019, 42, 263–279. [CrossRef]

9. Xie, H.; Paradise, B.D.; Ma, W.W.; Fernandez-Zapico, M. Recent Advances in the Clinical Targeting of Hedgehog/GLI Signaling in Cancer. Cells 2019, 8, 394. [CrossRef]

10. Huang, D.; Wang, Y.; Tang, J.; Luo, S. Molecular mechanisms of suppressor of fused in regulating the hedgehog signalling pathway (Review). Oncol. Lett. 2018, 15, 6077–6086. [CrossRef]

11. Petrova, R.; Joyner, A.L. Roles for Hedgehog signaling in adult organ homeostasis and repair. Development 2014, 141, 3445–3457. [CrossRef]

12. Sari, I.N.; Phi, L.T.H.; Jun, N.; Wijaya, Y.T.; Lee, S.; Kwon, H. Hedgehog Signaling in Cancer: A Prospective Therapeutic Target for Eradicating Cancer Stem Cells. Cells 2018, 7, 208. [CrossRef] [PubMed]

13. Skoda, A.M.; Simovic, D.; Karin, V.; Kardum, V.; Vranic, S.; Serman, L. The role of the Hedgehog signaling pathway in cancer: A comprehensive review. Bosn. J. Basic Med. Sci. 2018, 18, 8–20. [CrossRef] [PubMed]

14. Li, Q.-R.; Zhao, H.; Zhang, X.-S.; Lang, H.; Yu, K. Novel-smoothened inhibitors for therapeutic targeting of naive and drug-resistant hedgehog pathway-driven cancers. Acta Pharmacol. Sin. 2018, 40, 257–267. [CrossRef] [PubMed]

15. Xin, M.; Ji, X.; De La Cruz, L.K.; Thereja, S.; Wang, B. Strategies to target the Hedgehog signaling pathway for cancer therapy. Med. Res. Rev. 2018, 38, 870–913. [CrossRef]

16. Arensorf, A.M.; Marada, S.; Ogden, S.K. Smoothened Regulation: A Tale of Two Signals. Trends Pharmacol. Sci. 2015, 37, 62–72. [CrossRef]

17. Teperino, R.; Aberger, F.; Esterbauer, H.; Riobó, N.; Pospisilik, J.A. Canonical and non-canonical Hedgehog signalling and the control of metabolism. Semin. Cell Dev. Biol. 2014, 33, 81–92. [CrossRef]

18. Belgacem, Y.H.; Borodinsky, L.N. Sonic hedgehog signaling is decoded by calcium spike activity in the developing spinal cord. Proc. Natl. Acad. Sci. USA 2011, 108, 4482–4487. [CrossRef]

19. Polizio, A.H.; Chinchilla, P.; Chen, X.; Kim, S.; Manning, D.R.; Riobo, N.A. Heterotrimeric Gi Proteins Link Hedgehog Signaling to Activation of Rho Small GTPases to Promote Fibroblast Migration. J. Biol. Chem. 2011, 286, 19589–19596. [CrossRef]

20. Siegel, R.L.; Mph, K.D.M.; Jamal, A. Cancer statistics, 2020. CA Cancer J. Clin. 2020, 70, 7–30. [CrossRef]

21. Onitilo, A.A.; Engel, J.M.; Greenlee, R.T.; Mukesh, B.N. Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicoepidemiologic Features and Survival. Clin. Med. Res. 2009, 7, 4–13. [CrossRef]

22. Atkinson, R.L.; Yang, W.T.; Rosen, D.; Landis, M.D.; Wong, H.; Lewis, M.T.; Creighton, C.J.; Sexton, K.R.; Hilsenbeck, S.G.; Sahin, A.; et al. Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency. Breast Cancer Res. 2013, 15, R77. [CrossRef] [PubMed]

23. Tomao, F.; Papa, A.; Zaccarelli, E.; Rossi, L.; Caruso, D.; Minezzi, M.; Vici, P.; Frati, L.; Tomao, S. Triple-negative breast cancer: New perspectives for targeted therapies. OncoTargets Ther. 2015, 8, 177–193. [CrossRef]

24. Hui, M.; Cazet, A.S.; Nair, R.; Watkins, D.N.; O’Toole, S.; Swarbrick, A. The Hedgehog signalling pathway in breast development, carcinogenesis and cancer therapy. Breast Cancer Res. 2013, 15, 203. [CrossRef] [PubMed]

25. Flembø, A.; Qualtrough, D. The Potential Role of Hedgehog Signaling in the Luminal/Basal Phenotype of Breast Epithelia and in Breast Cancer Invasion and Metastasis. Cancers 2015, 7, 1863–1884. [CrossRef]

26. Riaz, S.K.; Khan, J.S.; Shah, S.T.A.; Wang, F.; Ye, L.; Jiang, W.G.; Malik, M.F.A. Involvement of hedgehog pathway in early onset, aggressive molecular subtypes and metastatic potential of breast cancer. Cell Comm. Signal. 2018, 16, 3. [CrossRef] [PubMed]
27. Tanaka, H.; Nakamura, M.; Kameda, C.; Kubo, M.; Sato, N.; Kuroki, S.; Tanaka, M.; Katano, M. The Hedgehog signaling pathway plays an essential role in maintaining the CD44+/CD24−/low subpopulation and the side population of breast cancer cells. *Anticancer Res.* **2009**, *29*, 2147–2157.

28. Cochrane, C.R.; Szczepny, A.; Watkins, D.N.; Cain, J.E. Hedgehog Signaling in the Maintenance of Cancer Stem Cells. *Cancers* **2015**, *7*, 1554–1585. [CrossRef]

29. Galdo, N.R.-D.; Montero, A.L.; Wertheimer, E.V. Role of Hedgehog Signaling in Breast Cancer: Pathogenesis and Therapeutics. *Cells* **2019**, *8*, 375. [CrossRef]

30. Moraes, R.C.; Zhang, X.; Harrington, N.; Fung, J.Y.; Wu, M.-F.; Hilsenbeck, S.G.; Allred, D.C.; Lewis, M.T. Constitutive activation of smoothened (SMO) in mammary glands of transgenic mice leads to increased proliferation, altered differentiation and ductal dysplasia. *Development* **2007**, *134*, 1231–1242. [CrossRef]

31. Visbal, A.P.; Laranca, H.L.; Villanueva, H.; Toneff, M.J.; Li, Y.; Rosen, J.M.; Lewis, M.T. Altered differentiation and paracrine stimulation of mammary epithelial cell proliferation by conditionally activated Smoothened. *Dev. Biol.* **2011**, *352*, 116–127. [CrossRef]

32. Jeng, K.-S.; Sheen, I.-S.; Jeng, W.-J.; Yu, M.-C.; Hsiau, H.-I.; Chang, F.-Y. High expression of Sonic Hedgehog signaling pathway genes indicates a risk of recurrence of breast carcinoma. *OncoTargets Ther.* **2013**, *7*, 79–86. [CrossRef] [PubMed]

33. Souzaki, M.; Kubo, M.; Kai, M.; Kameda, C.; Tanaka, H.; Taguchi, T.; Tanaka, M.; Onishi, H.; Katano, M. Hedgehog signaling pathway mediates the progression of non-invasive breast cancer to invasive breast cancer. *Cancer Sci.* **2010**, *102*, 373–381. [CrossRef] [PubMed]

34. Di Mauro, C.; Rosa, R.; D’Amato, V.; Ciciola, P.; Servetto, A.; Marciano, R.; Orsini, R.C.; Formisano, L.; De Falco, S.; Cicatiello, V.; et al. Hedgehog signaling pathway orchestrates angiogenesis in triple-negative breast cancers. *Br. J. Cancer* **2017**, *116*, 1425–1435. [CrossRef] [PubMed]

35. Menzl, I.; Lebeau, L.; Pandey, R.; Hassounah, N.B.; Li, F.; Nagle, R.; Weihs, K.L.; McDermott, K.M. Loss of primary cilia occurs early in breast cancer development. *Cilia* **2014**, *3*, 7. [CrossRef] [PubMed]

36. Li, L.; Tao, Y.; Mao, J.; Zhang, Q. Overexpression of Hedgehog signaling molecules and its involvement in primary cilia occurs early in breast cancer development. *Cilia* **2014**, *3*, 7. [CrossRef] [PubMed]

37. Harris, L.G.; Pannell, L.K.; Singh, S.; Samant, R.S.; Shevde, L.A. Increased vascularity and spontaneous metastasis of breast cancer by hedgehog signaling mediated upregulation of cyr61. *Oncogene* **2011**, *31*, 3370–3380. [CrossRef]

38. Cao, X.; Geradts, J.; Dewhurst, M.W.; Lo, H.-W. Upregulation of VEGF-A and CD24 gene expression by the tGLI1 transcription factor contributes to the aggressive behavior of breast cancer cells. *Oncogene* **2011**, *31*, 104–115. [CrossRef]

39. Guerrini, G.; Criscuoli, M.; Filippi, I.; Naldini, A.; Carraro, F. Inhibition of smoothened in breast cancer cells reduces CAXII expression and cell migration. *J. Cell. Physiol.* **2018**, *233*, 9799–9811. [CrossRef]

40. Kwon, Y.-J.; Hurst, D.R.; Steg, A.D.; Yuan, K.; Vaidya, K.S.; Welch, D.R.; Frost, A.R. Gli1 enhances migration and invasion via up-regulation of MMP-11 and promotes metastasis in ERα negative breast cancer cell lines. *Clin. Exp. Metastasis* **2011**, *28*, 437–449. [CrossRef]

41. Petersen, O.W.; Ronnov-Jessen, L.; Howlett, A.R.; Bissell, M.J. Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. *Proc. Natl. Acad. Sci. USA* **1992**, *89*, 9064–9068. [CrossRef]

42. Bartling, B.; Hofmann, H.-S.; Silber, R.-E.; Simm, A. Differential impact of fibroblasts on the efficient cell death of lung cancer cells induced by paclitaxel and cisplatin. *Cancer Biol. Ther.* **2008**, *7*, 1250–1261. [CrossRef] [PubMed]

43. Martinez-Outschoorn, U.E.; Sotgia, F.; Lisanti, M.P. Tumor Microenvironment and Metabolic Synergy in Breast Cancers: Critical Importance of Mitochondrial Fuels and Function. *Semin. Oncol.* **2014**, *41*, 195–216. [CrossRef] [PubMed]

44. Nieman, K.M.; A Kenny, H.; Penicka, C.V.; Ladányi, A.; Buell-Gutbrod, R.; Zillhardt, M.R.; Romero, I.L.; Carey, M.S.; Mills, G.B.; Hotamisligil, G.S.; et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. *Nat. Med.* **2011**, *17*, 1498–1503. [CrossRef] [PubMed]

45. Zhang, W.; Trachootham, D.; Liu, J.; Chen, G.; Pelicano, H.; Garcia-Prieto, C.; Lu, W.; Burger, J.A.; Croce, C.M.; Plunkett, W.; et al. Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. *Nat. Cell Biol.* **2012**, *14*, 276–286. [CrossRef] [PubMed]
46. Hanahan, D.; Coussens, L.M. Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment. *Cancer Cell* 2012, 21, 309–322. [CrossRef] [PubMed]
47. Laberge, R.-M.; Awad, P.; Campisi, J.; Desprez, P.-Y. Epithelial-Mesenchymal Transition Induced by Senescent Fibroblasts. *Cancer Microenvironment*. 2011, 5, 39–44. [CrossRef]
48. Martinez-Outschoorn, U.E.; Lin, Z.; Ko, Y.-H.; Goldberg, A.F.; Flomenberg, N.; Wang, C.; Pavlides, S.; Pestell, R.G.; Howell, A.; Sotgia, F.; et al. Understanding the metabolic basis of drug resistance. *Cell Cycle* 2011, 10, 2521–2526. [CrossRef]
49. Kamdje, A.H.N.; Etet, P.F.; Vecchio, L.; Tagne, R.S.; Amvene, J.M.; Muller, J.-M.; Krampera, M.; Lukong, K.E. New targeted therapies for breast cancer: A focus on tumor microenvironmental signals and chemoresistant breast cancers. *World J. Clin. Cases* 2014, 2, 769–786. [CrossRef]
50. Ruiz-Borrego, M.; Jimenez, B.; Antolín, S.; A Garcia-Saenz, J.; Corral, J.; Jerez, Y.; Trigo, J.; Urruticoechea, A.; Colom, H.; Gonzalo, N.; et al. A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012–12 (EDALINE) study. *Investig. New Drugs* 2018, 37, 98–108. [CrossRef]
51. Benvenuto, M.; Masuelli, L.; De Smaele, E.; Fantini, M.; Mattera, R.; Cucchi, D.; Bonanno, E.; Di Stefano, E.; Cucchi, D.; Vescovi, A.; et al. In vitro and in vivo inhibition of breast cancer cell growth by targeting the Hedgehog/GLI pathway with SMO (GDC-0449) or GLI (GANT-61) inhibitors. *OncoTarget* 2016, 7, 9250–9270. [CrossRef]
52. Kubo, M. Hedgehog Signaling Pathway is a New Therapeutic Target for Patients with Breast Cancer. *Cancer Res.* 2004, 64, 6071–6074. [CrossRef]
53. Das, S.; Samant, R.S.; Shevde, L.A. Hedgehog Signaling Induced by Breast Cancer Cells Promotes Osteoclastogenesis and Osteolysis. *J. Biol. Chem.* 2010, 286, 9612–9622. [CrossRef] [PubMed]
54. Sun, M.; Zhang, N.; Wang, X.; Li, Y.; Qi, W.; Zhang, H.; Li, Z.; Yang, Q. Hedgehog pathway is involved in nitidine chloride induced inhibition of epithelial-mesenchymal transition and cancer stem cells-like properties in breast cancer cells. *Cell Biosci.* 2016, 6, 44. [CrossRef] [PubMed]
55. Kameda, C.; Tanaka, H.; Yamasaki, A.; Nakamura, M.; Koga, K.; Sato, N.; Kubo, M.; Kuroki, S.; Tanaka, M.; Katano, M. The Hedgehog pathway is a possible therapeutic target for patients with estrogen receptor-negative breast cancer. *Anticancer Res.* 2009, 29, 871–879. [PubMed]
56. Shi, J.; Chai, F.; Zhou, J.; Chen, C.; Xie, S.; Chen, X.; Su, P. The Hedgehog inhibitor cyclopamine antagonizes chemoresistance of breast cancer cells. *Onco Targets Ther.* 2013, 6, 1643–1647. [CrossRef] [PubMed]
57. Che, J.; Zhang, F.-Z.; Zhao, C.-Q.; Hu, X.-D.; Fan, S.-J. Cyclopamine is a novel Hedgehog signaling inhibitor with significant anti-proliferative, anti-invasive and anti-estrogenic potency in human breast cancer cells. *Oncol. Lett.* 2013, 5, 1417–1421. [CrossRef] [PubMed]
58. Zhu, R.X.; Seto, W.-K.; Lai, C.-L.; Yuen, M.-F. Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region. *Gut Liver* 2016, 10, 332–339. [CrossRef] [PubMed]
59. Moon, H.; Cho, K.; Shin, S.; Kim, D.Y.; Han, K.-H.; Ro, S.W. High Risk of Hepatocellular Carcinoma Development in Fibrotic Liver: Role of the Hippo-YAP/TAZ Signaling Pathway. *Int. J. Mol. Sci.* 2019, 20, 581. [CrossRef]
60. Arzumanyan, A.; Reis, H.M.; Feitelson, M.A. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. *Nat. Rev. Cancer* 2013, 13, 123–135. [CrossRef]
61. Louvet, A.; Mathurin, P. Alcoholic liver disease: Mechanisms of injury and targeted treatment. *Nat. Rev. Gastroenterol. Hepatol.* 2015, 12, 231–242. [CrossRef]
62. Samal, J.; Kandpal, M.; Vivekanandan, P. Molecular Mechanisms Underlying Occult Hepatitis B Virus Infection. *Clin. Microbiol. Rev.* 2012, 25, 142–163. [CrossRef] [PubMed]
63. Stickel, F. Alcoholic cirrhosis and hepatocellular carcinoma. *Adv. Exp. Med. Biol.* 2015, 815, 113–130. [CrossRef] [PubMed]
64. Tsai, W.-L.; Chung, R.T. Viral hepatocarcinogenesis. *Oncogene* 2010, 29, 2309–2324. [CrossRef] [PubMed]
65. Heimbach, J.K. Liver Transplantation for Hepatocellular Carcinoma. *Cancer J.* 2008, 14, 95–99. [CrossRef] [PubMed]
66. Fonseca, A.L.; Cha, C.H. Hepatocellular carcinoma: A comprehensive overview of surgical therapy. *J. Surg. Oncol.* 2014, 110, 712–719. [CrossRef] [PubMed]
68. Jeng, K.S.; Sheen, I.S.; Jeng, W.J.; Lin, C.C.; Lin, C.K.; Su, J.C.; Yu, M.C.; Fang, H.Y. High Expression of Patched Homolog-1 Messenger RNA and Glioma-Associated Oncogene-1 RNA of Sonic Hedgehog Signaling Pathway Indicates a Risk of Postresection Recurrence of Hepatocellular Carcinoma. *Ann. Surg. Oncol.* 2012, 20, 464–473. [CrossRef]

69. Xu, Y.; Chenna, V.; Hu, C.; Sun, H.X.; Khan, M.; Bai, H.; Yang, X.R.; Zhu, Q.F.; Sun, Y.F.; Maitra, A.; et al. Polymeric Nanoparticle Encapsulated Hedgehog Pathway Inhibitor HPI-1 (“NanoHHI”) Inhibits Systemic Metastases in an Orthotopic Model of Human Hepatocellular Carcinoma. *Clin. Cancer Res.* 2011, 18, 1291–1302. [CrossRef]

70. Ding, X.; Yang, Y.; Han, B.; Du, C.; Xu, N.; Huang, H.; Cai, T.; Zhang, A.; Han, Z.G.; Zhou, W.; et al. Transcriptomic Characterization of Hepatocellular Carcinoma with CTNNB1 Mutation. *PLoS ONE* 2014, 9, e95307. [CrossRef]

71. Chun, H.W.; Hong, R. Significance of the hedgehog pathway-associated proteins Gli-1 and Gli-2 and the epithelial-mesenchymal transition-associated proteins Twist and E-cadherin in hepatocellular carcinoma. *Onco. Lett.* 2016, 12, 1753–1762. [CrossRef]

72. Michelotti, G.; Xie, G.; Swiderska, M.; Choi, S.S.; Karaca, G.; Kruger, L.; Premont, R.T.; Yang, L.; Syn, W.-K.; Metzger, D.; et al. Smoothered is a master regulator of adult liver repair. *J. Clin. Investig.* 2013, 123, 2380–2394. [CrossRef] [PubMed]

73. Chen, X.-L.; Cheng, Q.; She, M.; Wang, Q.; Huang, X.; Cao, L.-Q.; Fu, X.-H.; Chen, J.-S. Expression of Sonic Hedgehog Signaling Components in Hepatocellular Carcinoma and Cyclopamine-induced Apoptosis through Bcl-2 Downregulation in vitro. *Arch. Med. Res.* 2010, 41, 315–323. [CrossRef] [PubMed]

74. Sicklick, J.K.; Li, Y.-X.; Jayaraman, A.; Kannangai, R.; Qi, Y.; Vivekanandan, P.; Ludlow, J.W.; Owzar, K.; Chen, W.; Torbenson, M.S.; et al. Dysregulation of the Hedgehog pathway in human hepatocarcinogenesis. *Carcinogenesis* 2005, 27, 748–757. [CrossRef] [PubMed]

75. Cai, H.; Li, H.; Shi, Y.; Li, J.; Li, Y.; Wang, D.; Li, X. Sonic hedgehog signaling pathway mediates development of hepatocellular carcinoma. *Tumor. Biol.* 2016, 37, 16199–16205. [CrossRef] [PubMed]

76. Jeng, K.-S.; Sheen, I.-S.; Jeng, W.-J.; Yu, M.-C.; Hsiau, H.-I.; Chang, F.-Y.; Tsai, H.-H. Activation of the sonic hedgehog signaling pathway occurs in the CD133 positive cells of mouse liver cancer Hepa 1–6 cells. *OncoTargets Ther.* 2013, 6, 1047. [CrossRef]

77. Wang, P.; Song, W.; Li, H.; Wang, C.; Shi, B.; Guo, W.; Zhong, L. Association between donor and recipient smoothened gene polymorphisms and the risk of hepatocellular carcinoma recurrence following orthotopic liver transplantation in a Han Chinese population. *Tumor. Biol.* 2015, 36, 7807–7815. [CrossRef]

78. Tian, J.; Cheng, W.-T.; Zhang, Z.-G.; Liu, L.; Chen, Y.; Xü, K.; Tian, D.-Y. Role of Hedgehog signaling pathway in proliferation and invasiveness of hepatocellular carcinoma cells. *Int. J. Oncol.* 2009, 34, 829–836. [CrossRef]

79. Kim, Y.; Yoon, J.W.; Xiao, X.; Dean, N.M.; Monia, B.P.; Marcusson, E.G. Selective Down-Regulation of Glioma-Associated Oncogene 2 Inhibits the Proliferation of Hepatocellular Carcinoma Cells. *Cancer Res.* 2007, 67, 3583–3593. [CrossRef]

80. Arzumanyan, A.; Sambandam, V.; Clayton, M.M.; Choi, S.S.; Xie, G.; Diehl, A.M.; Yu, D.-Y.; Feitelson, M.A. Hedgehog signaling blockade delays hepatocarcinogenesis induced by hepatitis B virus X protein. *Cancer Res.* 2012, 72, 5912–5920. [CrossRef]

81. Jeng, K.-S.; Jeng, C.-J.; Jeng, W.-J.; Sheen, I.-S.; Chang, C.-F.; Hsiau, H.-I.; Hung, Z.-H.; Yu, M.-C.; Chang, F.-Y. Sonic hedgehog pathway inhibitor mitigates mouse hepatocellular carcinoma. *Am. J. Surg.* 2015, 210, 554–560. [CrossRef]

82. Jeng, K.-S.; Sheen, I.-S.; Jeng, W.-J.; Yu, M.-C.; Tsai, H.-H.; Chang, F.-Y.; Su, J.-C. Blockade of the sonic hedgehog pathway effectively inhibits the growth of hepatoma in mice: An in vivo study. *Oncol. Lett.* 2012, 4, 1158–1162. [CrossRef] [PubMed]

83. Liu, C.-H.; Lan, C.-T.; Chou, J.-F.; Tseng, T.-J.; Liao, W.-C. CHSY1 promotes aggressive phenotypes of hepatocellular carcinoma cells via activation of the hedgehog signaling pathway. *Cancer Lett.* 2017, 403, 280–288. [CrossRef] [PubMed]

84. Abou-Alfa, G.K.; Lewis, L.D.; Lorusso, P.; Maitland, M.; Chandra, P.; Cheeti, S.; Colburn, D.; Williams, S.; Simmons, B.; Graham, R.A. Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment. *Cancer Chemical. Pharmacol.* 2017, 80, 29–36. [CrossRef] [PubMed]

85. Machado, M.V.; Diehl, A.M. Hedgehog signalling in liver pathophysiology. *J. Hepatol.* 2018, 68, 550–562. [CrossRef]
94. Wang, Y.; Jin, G.; Li, Q.; Wang, Z.; Hu, W.; Li, P.; Li, S.; Wu, H.; Kong, X.; Gao, J.; et al. Hedgehog Signaling as a potential target to inhibit the progression of hepatocellular carcinoma. *OncoLett*. 2019, 18, 4377–4384. [CrossRef]

95. Wang, F.; Ma, L.; Zhang, Z.; Liu, X.; Gao, H.; Zhuang, Y.; Yang, P.; Kornmann, M.; Tian, X.; Yang, Y. Hedgehog signaling pathway as a potential target for treating pancreatic cancer. *Life Sci. Alliance*. 2016, 102, 408–417. [CrossRef] [PubMed]

96. Jeng, K.; Jeng, C.; Jeng, W.; Sheen, I.; Li, S.; Leu, C.-M.; Tsay, Y.; Chang, C.-F. Sonic Hedgehog signaling pathway as a potential target to inhibit the progression of hepatocellular carcinoma. *OncoLett*. 2019, 18, 4377–4384. [CrossRef]

97. Hwang, R.; Moore, T.T.; Hattersley, M.M.; Scarpitti, M.; Yang, B.; Devereaux, E.; Ramachandran, V.; Schweickert, P.G.; Yu, L.; et al. Inhibition of the hedgehog pathway targets the tumor-associated stroma in pancreatic cancer. *Mol. Cancer Res.* 2012, 10, 1147–1157. [CrossRef]

98. Olive, K.P.; Jacobetz, M.A.; Davidson, C.J.; Gopinathan, A.; McIntyre, D.; Honess, D.; Madhu, B.; Goldgrabin, M.A.; Caldwell, M.E.; Allard, D.; et al. Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer. *Science 2009*, 324, 1457–1461. [CrossRef]

99. Zhou, Q.; Zhou, Y.; Liu, X.; Shen, Y. GDC-0449 improves the antitumor activity of nano-doxorubicin in pancreatic cancer in a fibroblast-enriched microenvironment. *Sci. Rep.* 2017, 7, 13379. [CrossRef]

100. Liu, X.; Pitarelli, J.R.; Cuitino, M.C.; Kladney, R.D.; Woelke, S.A.; Sizemore, G.M.; Nayak, S.; Egriboz, O.; Schweickert, P.G.; Yu, L.; et al. Genetic ablation of Smoothened in pancreatic fibroblasts increases acinar–ductal metaplasia. *Gastroenterology*. 2016, 150, 1943–1955. [CrossRef]

101. Zeleznik, L.I.; Mph, K.D.M.; Sauer, A.G.; Fedewa, S.A.; Butterly, L.F.; Anderson, J.C.; Cercek, A.; Smith, R.A.; Jemal, A. Colorectal cancer statistics. 2020. *CA Cancer J. Clin.* 2020, 70, 145–164. [CrossRef] [PubMed]

102. Ding, L.; Wang, Q.-S.; Zhao, W.M.; Xiang, L. Expression of smoothened protein in colon cancer and its prognostic value for postoperative liver metastasis. *Asian Pac. J. Cancer Prev.* 2012, 13, 4001–4005. [CrossRef] [PubMed]
104. Li, T.; Liao, X.; Lochhead, P.; Morikawa, T.; Yamauchi, M.; Nishihara, R.; Inamura, K.; Kim, S.A.; Mima, K.; Sukawa, Y.; et al. SMO Expression in Colorectal Cancer: Associations with Clinical, Pathological, and Molecular Features. *Ann. Surg. Oncol.* 2014, 21, 4164–4173. [CrossRef] [PubMed]

105. Regan, J.L.; Schumacher, D.; Staude, S.; Steffen, A.; Haybaeck, J.; Keilholz, U.; Schweiger, C.; Golob-Schwarzl, N.; Mumberg, D.; Henderson, D.; et al. Non-Canonical Hedgehog Signaling Is a Positive Regulator of the WNT Pathway and Is Required for the Survival of Colon Cancer Stem Cells. *Cell Rep.* 2017, 21, 2813–2826. [CrossRef]

106. Zhang, X.; Zhang, S.-S.; Wei, G.-J.; Deng, Z.-M.; Hu, Y. Dysregulation of hedgehog signaling pathway related components in the evolution of colon carcinogenesis. *Int. J. Clin. Exp. Med.* 2015, 8, 21379–21385.

107. Guleng, B.; Tateishi, K.; Ohta, M.; Asaoka, Y.; Jazag, A.; Lin, L.-J.; Tanaka, Y.; Tada, M.; Seto, M.; Kanai, F.; et al. Smoothened gene mutations found in digestive cancer have no aberrant Hedgehog signaling activity. *J. Gastroenterol.* 2007, 41, 1238–1239. [CrossRef]

108. Chatel, G.; Ganeff, C.; Boussif, N.; Delacroix, L.; Briquet, A.; Nolens, G.; Winkler, R. Hedgehog signaling pathway is inactive in colorectal cancer cell lines. *Int. J. Cancer* 2007, 121, 2622–2627. [CrossRef]

109. Gerling, M.; Büller, N.V.J.A.; Kirn, L.M.; Joost, S.; Frings, O.; Englert, B.; Bergström, Å.; Kuiper, R., Blaas, L.; Wielenga, M.C.B.; et al. Stromal Hedgehog signalling is downregulated in colon cancer and its restoration restrains tumour growth. *Nat. Commun.* 2016, 7, 12321. [CrossRef]

110. Wu, C.; Hu, S.; Cheng, J.; Wang, G.; Tao, K. Smoothened antagonist GDC-0449 (Vismodegib) inhibits proliferation and triggers apoptosis in colon cancer cell lines. *Exp. Ther. Mol. Biol.* 2017, 13, 2529–2536. [CrossRef]

111. Magistri, P.; Battistelli, C.; Strippoli, R.; Petrucciani, N.; Pellinen, T.; Rossi, L.; Mangogna, L.; Aurello, P.; D’Angelo, F.; Tripodi, M.; et al. SMO Inhibition Modulates Cellular Plasticity and Invasiveness in Colorectal Cancer. *Front. Pharmacol.* 2018, 9, 956. [CrossRef]

112. Ruat, M.; Hoch, L.; Faure, H.; Rognan, D. Targeting of Smoothened for therapeutic gain. *Trends Pharmacol. Sci.* 2014, 35, 237–246. [CrossRef] [PubMed]

113. Rimkus, T.K.; Carpenter, R.L.; Qasem, S.; Chan, M.; Lo, H.-W. Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors. *Cancers* 2016, 8, 22. [CrossRef] [PubMed]

114. Kim, E.J.; Sahai, V.; Abel, E.V.; Gri...
122. Fu, J.; Rodova, M.; Nanta, R.; Meeker, D.; Van Veldhuizen, P.J.; Srivastava, R.K.; Shankar, S. NPV-LDE-225 (Erismodigib) inhibits epithelial mesenchymal transition and self-renewal of glioblastoma initiating cells by regulating miR-21, miR-128, and miR-200. *Neuro-oncology* 2013, 15, 691–706. [CrossRef] [PubMed]

123. Nanta, R.; Kumar, D.; Meeker, D.; Rodova, M.; Van Veldhuizen, P.J.; Shankar, S.; Srivastava, R.N. NVP-LDE-225 (Erismodigib) inhibits epithelial–mesenchymal transition and human prostate cancer stem cell growth in NOD/SCID IL2Ry null mice by regulating Bmi-1 and microRNA-128. *Oncogenesis* 2013, 2, e42. [CrossRef] [PubMed]

124. Campbell, V.T.; Nadesan, P.P.; Wang, Y.; Whetstone, H.; McGovern, K.; Read, M.; Alman, B.A.; Wunder, J.S.; Wang, C.Y. Abstract LB-380: Direct targeting of the Hedgehog pathway in primary chondrosarcoma xenografts with the Smoothed inhibitor IPI-926. *Exp. Mol. Ther.* 2011, 71. [CrossRef]

125. Travaglione, V.; Peacock, C.; MacDougall, J.; McGovern, K.; Cushing, J.; Yu, L.C.; Trudeau, M.; Palombella, V.; Adams, J.; Hierman, J. A novel HH pathway inhibitor, IPI-926, delays recurrence post-chemotherapy in a primary human SCLC xenograft model. *Tumor Biol.* 2008, 29, 4611.

126. Riedlinger, D.; Bahra, M.; Boas-Knoop, S.; Lippert, S.; Bradtmöller, M.; Guse, K.; Seehofer, D.; Bova, R.; Sauer, I.M.; Neuhaus, P. Hedgehog pathway as a potential treatment target in human cholangiocarcinoma. *J. Hepato-Biliary-Pancreat. Sci.* 2014, 21, 607–615. [CrossRef]

127. Rohner, A.; Spilker, M.E.; Lam, J.L.; Pascual, B.; Bartkowski, D.; Li, Q.J.; Yang, A.H.; Stevens, G.; Xu, M.; Wells, P.A.; et al. Effective Targeting of Hedgehog Signaling in a Medulloblastoma Model with PF-5274857, a Potent and Selective Smoothed Antagonist That Penetrates the Blood-Brain Barrier. *Mol. Cancer Ther.* 2011, 11, 57–65. [CrossRef]

128. Kogame, A.; Tagawa, Y.; Shibata, S.; Tojo, H.; Miyamoto, M.; Tohyama, K.; Kondo, T.; Prakash, S.; Shyu, W.C.; Asahi, S. Pharmacokinetic and Pharmacodynamic Modeling of Hedgehog Inhibitor TAK-441 for the Inhibition of Gli1 messenger RNA Expression and Antitumor Efficacy in Xenografted Tumor Model Mice. *Drug Metab. Dispos.* 2013, 41, 727–734. [CrossRef]

129. Katoh, M. Genomic testing, tumor microenvironment and targeted therapy of Hedgehog-related human cancers. *Clin. Sci.* 2019, 133, 953–970. [CrossRef]

130. Liao, S.; Floyd, C.; Verratti, N.; Leung, L.; Wu, C. Analysis of vismodegib resistance in D473G and W535L mutants of SMO receptor and design of novel drug derivatives using molecular dynamics simulations. *Life Sci.* 2020, 244, 117302. [CrossRef]

131. Peer, E.; Tesanovic, S.; Aberger, F. Next-Generation Hedgehog/GLI Pathway Inhibitors for Cancer Therapy. *Cancers* 2019, 11, 538. [CrossRef]

132. Khatra, H.; Bose, C.; Sinha, S. Discovery of Hedgehog Antagonists for Cancer Therapy. *Curr. Med. Chem.* 2017, 24, 1. [CrossRef] [PubMed]

133. Almuraikhi, N.; Almasoud, N.; Binhamdan, S.; Younis, G.; Ali, D.; Manikandan, M.; Vishnubalaji, R.; Atteya, M.; Siyal, A.; Alfayez, M.; et al. Hedgehog Signaling Inhibition by Smoothed Antagonist BMS-833923 Reduces Osteoblast Differentiation and Ectopic Bone Formation of Human Skeletal (Mesenchymal) Stem Cells. *Stem Cells Int.* 2019, 2019, 3435901-12. [CrossRef] [PubMed]

134. Yoon, C.; Park, J.; Schmidt, B.; Thomas, N.J.; Lee, H.-J.; Kim, T.; Janjigian, Y.Y.; Cohen, D.J.; Yoon, S.S. CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistance. *Clin. Cancer Res.* 2014, 20, 3974–3988. [CrossRef] [PubMed]

135. Du, F.-Y.; Zhou, Q.-F.; Sun, W.-J.; Chen, G. Targeting cancer stem cells in drug discovery: Current state and future perspectives. *World J. Stem Cells* 2019, 11, 398–420. [CrossRef] [PubMed]

136. Miyamoto, T.; Weissman, I.L.; Akashi, K. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. *Proc. Natl. Acad. Sci. USA* 2000, 97, 7521–7526. [CrossRef]

137. Cozzio, A.; Passegué, E.; Ayton, P.M.; Karsunky, H.; Cleary, M.L.; Weissman, I.L. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. *Genes Dev.* 2003, 17, 3029–3035. [CrossRef]

138. Savage, P. Chemotherapy curable malignancies and cancer stem cells: A biological review and hypothesis. *BMC Cancer* 2016, 16, 1–11. [CrossRef]

139. An, S.M.; Ding, Q.; Zhang, J.; Xie, J.; Li, L. Targeting stem cell signaling pathways for drug discovery: Advances in the Notch and Wnt pathways. *Sci. China Life Sci.* 2014, 57, 575–580. [CrossRef]
140. Xu, Y.; Song, S.; Wang, Z.; Ajani, J.A. The role of hedgehog signaling in gastric cancer: Molecular mechanisms, clinical potential, and perspective. Cell Commun. Signal. 2019, 17, 1–10. [CrossRef]

141. Briscoe, J.; Théron, P.P. The mechanisms of Hedgehog signalling and its roles in development and disease. Nat. Rev. Mol. Cell Biol. 2013, 14, 416–429. [CrossRef]

142. Ramos, E.K.; Hoffmann, A.D.; Gerson, S.L.; Liu, H. New Opportunities and Challenges to Defeat Cancer Stem Cells. Trends Cancer 2017, 3, 780–796. [CrossRef] [PubMed]

143. Feldmann, G.; Fendrich, V.; McGovern, K.; Bedja, D.; Bisht, S.; Alvarez, H.; Koorstra, J.-B.M.; Habbe, N.; Karikari, C.; Mullendore, M.; et al. An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Mol. Cancer Ther. 2008, 7, 2725–2735. [CrossRef] [PubMed]

144. Varnat, F.; Duquet, A.; Malerba, M.; Zbinden, M.; Mas, C.; Gervaz, P.; Ruiz i Altaba, A. Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion. EMBO Mol. Med. 2009, 1, 338–351. [CrossRef]

145. Kurebayashi, J.; Koike, Y.; Ohta, Y.; Saitoh, W.; Yamashita, T.; Kanomata, N.; Moriya, T. Anti-cancer stem cell activity of a hedgehog inhibitor GANT61 in estrogen receptor-positive breast cancer cells. Cancer Sci. 2017, 108, 918–930. [CrossRef]

146. Xu, M.; Gong, A.; Yang, H.; George, S.K.; Jiao, Z.; Huang, H.; Jiang, X.; Zhang, Y. Sonic hedgehog-glioma associated oncogene homolog 1 signaling enhances drug resistance in CD44+/Musashi-1+ gastric cancer stem cells. Cancer Lett. 2015, 369, 124–133. [CrossRef]

147. Peiris-Pagés, M.; Sotgia, F.; Lisanti, M.P. Chemotherapy induces the cancer-associated fibroblast phenotype, activating paracrine Hedgehog-GLI signalling in breast cancer cells. Oncotarget 2015, 6, 10728–10745. [CrossRef] [PubMed]

148. Li, W.; Yang, H.; Li, X.; Han, L.; Xu, N.; Shi, A. Signaling pathway inhibitors target breast cancer stem cells in triple-negative breast cancer. Oncol. Rep. 2018, 41, 437–446. [CrossRef]

149. Galperin, I.; Dempwolff, L.; Diederich, W.E.; Lauth, M. Inhibiting Hedgehog: An Update on Pharmacological Compounds and Targeting Strategies. J. Med. Chem. 2019, 62, 8392–8411. [CrossRef] [PubMed]

150. Clara, J.A.; Monge, C.; Yang, Y.; Takebe, N. Targeting signalling pathways and the immune microenvironment of cancer stem cells—A clinical update. Nat. Rev. Clin. Oncol. 2019, 17, 204–232. [CrossRef]

151. Wagner, A.J.; Messersmith, W.A.; Shaik, M.N.; Li, S.; Zheng, X.; McLachlan, K.R.; Cesari, R.; Courtney, R.; Levin, W.J.; El-Khoueiry, A.B. A Phase I Study of PF-04449913, an Oral Hedgehog Inhibitor, in Patients with Advanced Solid Tumors. Clin. Cancer Res. 2014, 21, 1044–1051. [CrossRef]

152. Jeng, K.-S.; Chang, C.-F.; Jeng, W.-J.; Sheen, I.-S.; Jeng, C.-J. Heterogeneity of hepatocellular carcinoma contributes to cancer progression. Crit. Rev. Oncol. 2015, 94, 337–347. [CrossRef]

153. Sharpe, H.J.; Pau, G.; Dijkgraaf, G.J.; Basset-Séguin, N.; Modrusan, Z.; Januario, T.; Tsui, V.; Durham, A.B.; Dlugosz, A.A.; Haverty, P.M.; et al. Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. Cancer Cell 2015, 27, 327–341. [CrossRef] [PubMed]

154. Lu, W.; Zhang, D.; Ma, H.; Tian, S.; Zheng, J.; Wang, Q.; Luo, L.; Zhang, X. Discovery of potent and novel smoothened antagonists via structure-based virtual screening and biological assays. Eur. J. Med. Chem. 2018, 155, 34–48. [CrossRef] [PubMed]

155. Cortes, J.; Gutzmer, R.; Kieran, M.W.; Solomon, J.A. Hedgehog signaling inhibitors in solid and hematological cancers. Cancer Treat. Rev. 2019, 76, 41–50. [CrossRef] [PubMed]